Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: A phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC).

2552Background: Our preclinical data show that one mechanism of acquired resistance to anti-angiogenic therapy involves hypoxia correction, measured by decreased SUV ( ↓ SUV) on FDG-PET followed by...